J Korean Ophthalmol Soc > Volume 51(8); 2010 > Article
Journal of the Korean Ophthalmological Society 2010;51(8):1071-1076.
DOI: https://doi.org/10.3341/jkos.2010.51.8.1071    Published online August 15, 2010.
Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Hosoong Kim, Sangjung Moon, Jaehoon Kang, Heesung Yoon
Sungmo Eye Hospital, Korea. heesyoon@dreamwiz.com
망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 트리암시놀론주입술과 베바시주맙주입술의 비교
김호숭ㆍ문상정ㆍ강재훈ㆍ윤희성
Sungmo Eye Hospital
Abstract
PURPOSE
To compare clinical outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion. METHODS: Sixty-six patients received an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed. Thirty-three out of 66 patients were treated with an intravitreal injection of triamcinolone acetonide, while the other 33 patients received a bevacizumab injection. All patients underwent a visual acuity test, optical coherence tomography imaging and ophthalmoscopic examination throughout the follow-up. RESULTS: In the triamcinolone group, central macular thickness (CMT) decreased from 496.69 +/- 153.01 micrometer at baseline to 313.06 +/- 150.14 micrometer at the six-month follow-up visit, while in the bevacizumab group, CMT decreased from 441.30 +/- 185.79 micrometer to 295.67 +/- 188.80 micrometer (p<0.05). In the triamcinolone group, best-corrected visual acuity (BCVA) improved from logMAR 0.92 +/- 0.70 at baseline to logMAR 0.53 +/- 0.43 at the six-month follow-up visit, and in the bevacizumab group, BCVA improved from logMAR 0.74 +/- 0.47 to logMAR 0.34 +/- 0.33 (p<0.05). CONCLUSIONS: The therapeutic effects of intravitreal triamcinolone acetonide showed no significant differences compared with those of intravitreal bevacizumab with regard to anatomical and functional outcomes.
Key Words: Bevacizumab;Branch retinal vein occlusion;Macular edema;Triamcinolone


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next